470 related articles for article (PubMed ID: 19121849)
1. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
2. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
Miyata Y; Kanetake H; Kanda S
Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
[TBL] [Abstract][Full Text] [Related]
4. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
5. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
6. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
7. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma.
Xie LQ; Bian LJ; Li Z; Li Y; Li ZX; Li B
Ann Surg Oncol; 2010 Jul; 17(7):1927-36. PubMed ID: 20131016
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T
Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
[TBL] [Abstract][Full Text] [Related]
16. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.
Chen YS; Wang JT; Chang YF; Liu BY; Wang YP; Sun A; Chiang CP
J Oral Pathol Med; 2004 Apr; 33(4):209-17. PubMed ID: 15061708
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
Gakiopoulou H; Nakopoulou L; Siatelis A; Mavrommatis I; Panayotopoulou EG; Tsirmpa I; Stravodimos C; Giannopoulos A
Clin Cancer Res; 2003 Nov; 9(15):5573-81. PubMed ID: 14654538
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
19. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
Dong P; Li X; Yu Z; Lu G
J Laryngol Otol; 2007 Dec; 121(12):1177-83. PubMed ID: 17888194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
